US Patent

US7799331 — Oral suspension of prednisolone acetate

Method of Use · Assigned to Taro Pharmaceuticals North America Inc · Expires 2028-10-11 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a novel oral suspension formulation of prednisolone acetate for treating patients in need of the drug.

USPTO Abstract

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Drugs covered by this patent

prednisolone-acetate (PREDNISOLONE ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1068`	—	prednisolone-acetate
`U-139`	—	prednisolone-acetate

Patent Metadata

Patent number: US7799331
Jurisdiction: US
Classification: Method of Use
Expires: 2028-10-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Taro Pharmaceuticals North America Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.